Quanterix (NASDAQ:QTRX – Get Rating) is set to post its quarterly earnings results before the market opens on Tuesday, May 10th. Analysts expect Quanterix to post earnings of ($0.64) per share for the quarter.
Quanterix (NASDAQ:QTRX – Get Rating) last released its quarterly earnings results on Tuesday, March 1st. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.11. The firm had revenue of $29.31 million for the quarter, compared to analysts’ expectations of $29.00 million. Quanterix had a negative net margin of 52.18% and a negative return on equity of 12.58%. During the same quarter last year, the company earned ($0.31) EPS. On average, analysts expect Quanterix to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:QTRX traded down $0.97 during trading hours on Wednesday, reaching $22.17. 213 shares of the company were exchanged, compared to its average volume of 245,567. The firm has a market cap of $816.96 million, a PE ratio of -14.46 and a beta of 1.59. Quanterix has a twelve month low of $21.13 and a twelve month high of $69.22. The stock’s 50-day moving average is $27.48 and its 200-day moving average is $35.82.
A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc lifted its position in Quanterix by 2.8% during the fourth quarter. Legal & General Group Plc now owns 13,027 shares of the company’s stock worth $552,000 after buying an additional 354 shares in the last quarter. Deutsche Bank AG raised its position in Quanterix by 5.1% in the fourth quarter. Deutsche Bank AG now owns 21,253 shares of the company’s stock valued at $901,000 after purchasing an additional 1,026 shares during the period. UBS Group AG raised its position in Quanterix by 45.4% in the third quarter. UBS Group AG now owns 12,216 shares of the company’s stock valued at $608,000 after purchasing an additional 3,813 shares during the period. Geode Capital Management LLC raised its position in Quanterix by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 569,260 shares of the company’s stock valued at $24,136,000 after purchasing an additional 3,986 shares during the period. Finally, Citigroup Inc. raised its position in Quanterix by 109.3% in the fourth quarter. Citigroup Inc. now owns 8,467 shares of the company’s stock valued at $359,000 after purchasing an additional 4,422 shares during the period. Hedge funds and other institutional investors own 86.46% of the company’s stock.
A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Quanterix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 26th. JPMorgan Chase & Co. lowered their price target on Quanterix from $85.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. SVB Leerink dropped their price target on Quanterix from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Finally, The Goldman Sachs Group decreased their price objective on Quanterix from $40.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, April 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $54.60.
Quanterix Company Profile (Get Rating)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
- Get a free copy of the StockNews.com research report on Quanterix (QTRX)
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.